Comparative Pharmacology
Head-to-head clinical analysis: DOBUTAMINE HYDROCHLORIDE versus INOCOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOBUTAMINE HYDROCHLORIDE versus INOCOR.
DOBUTAMINE HYDROCHLORIDE vs INOCOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dobutamine directly stimulates β1-adrenergic receptors in the heart, increasing myocardial contractility and stroke volume with minimal chronotropic effect at therapeutic doses. It also has mild β2 and α1 activity.
Inocor (amrinone) is a phosphodiesterase III inhibitor that increases intracellular cAMP in cardiac and vascular smooth muscle, leading to positive inotropic effects and vasodilation.
Intravenous infusion: 2.5-20 mcg/kg/min, titrated to hemodynamic response. Typical starting dose 2.5-5 mcg/kg/min.
Initial intravenous bolus of 0.75 mg/kg over 2-3 minutes, followed by a continuous infusion of 5-10 mcg/kg/min. Maximum dose: 10 mg/kg/day.
None Documented
None Documented
2-3 minutes (short distribution half-life). Terminal elimination half-life is approximately 2 minutes. Clinical context: Requires continuous intravenous infusion for sustained effect due to rapid clearance.
Terminal elimination half-life: 2.4 hours in normal renal function; prolonged in renal impairment (up to 6 hours in ESRD).
Primarily renal (90-95% as inactive metabolites, mainly glucuronide conjugates and 3-O-methyl metabolites). Less than 5% excreted unchanged. Biliary/fecal elimination is minimal (<5% in feces).
Primarily renal (80%) as unchanged drug; 20% biliary/fecal.
Category C
Category C
Inotropic Agent
Inotropic Agent